For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Tafamidis meglumine represents a true change. These innovative therapies preserve the transthyretin protein, slowing its destructive build-up and lessening the severity o